|
Post by trenddiver on Nov 24, 2015 0:41:09 GMT -5
Well, shorts have the company exactly where they have wanted it for quite a while, apparently out of options. To tell the truth, the more I learned about MNKD the more I felt there was a power play between Mann and other interests set on controlling the corporation or at least a big part of it. Mann is fairly mighty and he might have thought he had a chance to win in this game, but I can now, with some certainty level, can say that it appears the opposite side has the upper hand and therefore the interests behind it must be extremely well financed and connected. A part of me thinks that the best that could happen for long term investors is that Mann gives in to pressure and accommodates the interest of those involved in the game. I have a feeling that the sp would quickly jump considerably if this happened. Unfortunately or fortunately, depending on how you perceive the issue, I do not think Mann will give in, but then again he is in his 90s. His enemies have proven that they are willing to patiently wait for a long time. What are you talking about? What interest is he supposed to accommodate? Don't underestimate Al, he has huge firepower ($3 billion) he chooses to use it.
|
|
|
Post by trenddiver on Nov 24, 2015 0:36:53 GMT -5
If we were to see Matt bail, then I believe that would be the red herring we could/should use to make a pivotal investment decision. Right now, with Al back at the reigns, any number of things could be agreed to that would improve the current predicament. If Matt were to walk, that would definitely be reason to pause. If Matt were to resign, I'd back up the truck and buy, buy, buy. I personally hold Matt responsible for the horrible financial shape that the company is in. Trend
|
|
|
Post by trenddiver on Nov 22, 2015 2:08:55 GMT -5
Peppy, I'm one of those who believes that gettiing the product back from a Sanofi could be a windfall. 1. We keep the $200 million that they gave us. 2. The $125 million start up expenses for the launch - 65% of which was paid for by Sanofi accrues to our benefit at no charge (except for the money we owe Sanofi) 3. Sanofi's 65% ownership interest in Afrezza accrues to Mannkind at no charge. 4. The $45 million that Mannkind owes to Sanofi doesn't have to repaid for 10 years. 5. Mannkind will have complete control over the distribution of Afrezza and can control there own destiny. If Mannkind needed to raise addition capital to support this windfall, I would jump off the fence and add to my position. Trend Payor negotiation ( formulary placements) and trials needed /mandated by FDA are important things that SNY is needed for. We all know MNKD had trouble even designing the trials..lol.. if the trials were originally designed for superior label, we wouldnt be in this position.. and market is not only US .. Rest of the world? MNKD has no resources/expertise outside of US. You talk about distribution control..thats Sanofi's. MNKD has no distrubtion , but its relatively small issue as it can be outsourced ( but $$$) so we can put the thought that MNKD can go solo to rest....when MNKD had to dilute 10% to get by the next qtr.. Be realistic - not emotional If I didn't know better, I'd swear you were Obama telling us that getting rid of Isis is just to tough to go it alone. I know that there are many challenges, but 100% of something is better than 35% of nothing.
|
|
|
Post by trenddiver on Nov 21, 2015 18:43:08 GMT -5
Crazy talk; over on the other thread, they are talking about sanofi dropping us. Tell me what is wrong with my thinking. I can see a case where, we want out of sanofi. we need to be priced right. the ground work done at some level and we do not have to pay them back for 10 years. We have the insulin and a contract. hmmm Peppy, I'm one of those who believes that gettiing the product back from a Sanofi could be a windfall. 1. We keep the $200 million that they gave us. 2. The $125 million start up expenses for the launch - 65% of which was paid for by Sanofi accrues to our benefit at no charge (except for the money we owe Sanofi) 3. Sanofi's 65% ownership interest in Afrezza accrues to Mannkind at no charge. 4. The $45 million that Mannkind owes to Sanofi doesn't have to repaid for 10 years. 5. Mannkind will have complete control over the distribution of Afrezza and can control there own destiny. If Mannkind needed to raise addition capital to support this windfall, I would jump off the fence and add to my position. Trend
|
|
|
Post by trenddiver on Nov 20, 2015 20:06:20 GMT -5
trenddiver, I wish this were the case but I think it should be obvious at this point that us retails are simply along for the ride. Al and institutions owning so many shares make this a game where we have virtually no representation despite the fact this it is a publicly traded company. I doubt Al at the helm will equal more transparency, possibly the opposite; Al hasn't ever been very shareholder friendly, we are just a means to an end for him. Hopefully the new CEO will be both forthcoming and polished in PR (unlike Mr. Hakan, I'll never be able to forget his cringeworthy words during that last CC), we shall soon find out. Jeremg, I have spoken with Al at at a couple of shareholder meetings and I have to disagree with you about Al and his feelings towards shareholders. I believe he genuinely does care about retail shareholders because many of the investors in Mannkind are his longterm friends. In addition many of his relatives are shareholders. When you meet Al, he just seems like one of the guys (he even took pictures with the "nurses" He was always open and frank, sometimes to a fault. At the last shareholder meeting that I attended in 2014, someone asked Al a question about Mannkind and its future, And Al answered that Mannkind was about "patients and shareholders" and the future was bright. I think Al believed this when he said it, and hope he still believes it. That why I'm still holding my shares. Trend
|
|
|
Post by trenddiver on Nov 20, 2015 18:39:11 GMT -5
I think Al needs to have a conference call ASAP with shareholders and others to explain what just happened and give his views of the present situation with Mannkind, Sanofi, Technosphere. He also needs to give us his vision of the future. Many of us are in this investment because of Al Mann and our trust in him a a leader and entrepreneur, and a visionary. Al needs to reassure us that his vision is intact and he will take the necessary steps to get back on track. I think this needs to be done in the next week or so. I hope Al is reading our board and gets this message. (I have no direct knowledge that he does, but wouldn't be surprised).
Trend
|
|
|
Post by trenddiver on Nov 20, 2015 10:43:32 GMT -5
Matt has done magnificently he is CFO not CEO. Without sales traction, he either hatched or managed the TASE deal , which with Al's loans gets us another 12 months. What more could you ask a CFO to do - he's staved off bankruptcy. This action today is Al working on the Sales side. Expect the relationship with SNY to get a lot more animated in the near term: they basically cant park Afrezza now and wait for MNKD to die (finances covered, and more aggressive CEO - either Al himself or newcomer) How about this for starters. He could have raised capital for the company when the SP was 10 not 2. If anyone is responsible for MNKD's low cash position and potential bankruptcy talk, it's Matt.
|
|
|
Post by trenddiver on Nov 20, 2015 10:38:25 GMT -5
Wherever Hakan goes, I hope he takes Matt with him. We need to clear the decks and start fresh with a a top flight CEO and CFO. Trend Too much instability. Matt speaks well on the CC.
The CFO's primary job in a public company is dealing with Wall Street and making sure the Company has sufficient capital for current and future needs. In my opinion I'd rate his job performance an F.
|
|
|
Post by trenddiver on Nov 20, 2015 10:15:24 GMT -5
Wherever Hakan goes, I hope he takes Matt with him. We need to clear the decks and start fresh with a a top flight CEO and CFO.
Trend
|
|
|
Post by trenddiver on Nov 20, 2015 8:06:08 GMT -5
Negative opinion on new medicine The CHMP adopted a negative opinion for Solumarv (insulin human) which was expected to be used to treat patients with diabetes who require insulin to control their blood sugar levels. Solumarv was developed as a biosimilar medicine. For more information, please see the questions-and-answers document in the grid below. -------------------------------------------------------------------------------------------------------------------------------------------------- Negative recommendation on new medicine Name of medicine Solumarv International non-proprietary name (INN) insulin human Marketing-authorisation applicant Marvel Life Sciences Ltd Therapeutic indication Treatment of diabetes More information Questions and answers on Solumarv www.google.ie/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=SolumarvI think we should let Marvel Science LTD and its biosimiliar human Insulin attempts go gently into the night. Its amazing how much time and energy is wasted on this board speculating, analyzing, dissecting, writing about all this nonsense. Surely you folks have better things to do. Trend
|
|
|
Post by trenddiver on Nov 19, 2015 16:51:25 GMT -5
BoD is still in session as of Thursday today 11/19/15. Pain/Migraine partnership is being discussed as one of topics. Pain med passed animal trial, was ready for human clinical trial. It's furthest along among APIs. Please do your own DD before passing judgement.You can partially verify some. Do not lock this thread just because you can't verify on your own for the benefit of others, out of respect for the long-suffering Old Faithfuls such as rock, kball, dbc, mnholdem, kc, spiro, rob, resident PCPs, ... You gotta love this guy Lakers. Even if he is right or wrong, he is the best tease on the board. Trend
|
|
|
Post by trenddiver on Nov 18, 2015 0:18:16 GMT -5
Quote: Do you have any additional insight to offer? if Sanofi is to supply the insulin API for Afrezza it will have to be approved which is “not a trivial process,” according to Pfeffer. Reply; Yes, I do have additional insight. You said it would take a phone call and then you posted it takes more than a phone call. I see you thought about it enough to find out, it takes more than a phone call. This discussion is over for me.
"You said it would take a phone call..." No, I said I thought it would take little more than a "phone call" given the huge amount of insulin SNY already sells in the United States. Does anyone see any reason why it should take 14 months or longer? Is SNY even attempting to get qualified to supply insulin to MNKD? Rrtz Just wondering why you are here? Do you own shares? Are you short? I have yet to see any post from you other than a negative slant. I not saying that your soft bashing isn't welcome or that from time to time you don't raise an interesting point to two, but what is your purpose here. Trend
|
|
|
Post by trenddiver on Nov 17, 2015 22:36:16 GMT -5
What a frustrating company to be interested in! jpg Why are you frustrated? I thought I remember you posting recently that you sold your entire positions. Tren
|
|
|
Post by trenddiver on Nov 16, 2015 17:33:53 GMT -5
I can't give you a market value for Afrezza and Technospere, but it is my belief that the value is higher than the current market capitalization. Time will tell who is correct. Well if you believe that, you better be backing up the truck.
|
|
|
Post by trenddiver on Nov 16, 2015 12:30:12 GMT -5
The only important thing to change right now is much stronger effort to get the insurance situation right. I am sure mgt is working as hard as they can on the other points. The additional information we need is why SNY with all its world wide presence has not filed applications in more countries and when they plan to do so. I agree that from a business standpoint your points are very valid. However even if those business issues are solved in the near term, Mannkind will still have significant cash requirements over the next couple of years. But Mannkind must address these cash flow requirements NOW. Every competent CFO and business owner knows that you have to address cash needs way in advance of the actual need. Mannkind should have raised several hundred million dollars a year ago, when the SP was much higher. When you seek capital at a time when cash is needed, the cost (dilution) becomes very expensive as we have seen recently. I lay this criticism directly in the lap of Big Al and Matt, they should know better. The short interest bankruptcy argument must be taken off the table with a well thought out capital raising effort. Mannkind must be able to capitalize on its Technosphere technology without having to make a bad deal because of its short term cash needs. Trend
|
|